Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrucci, Maria Teresa, Finsinger, Paola, Chisini, Marta, Gentilini, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094627/
https://www.ncbi.nlm.nih.gov/pubmed/25045252
http://dx.doi.org/10.2147/PPA.S38142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094627/
https://www.ncbi.nlm.nih.gov/pubmed/25045252
http://dx.doi.org/10.2147/PPA.S38142

Ejemplares similares